Benefits
Universal antioxidant
Unlike most antioxidants, ALA and its reduced form DHLA are active in both aqueous and lipid environments, and can regenerate other antioxidants including vitamins C and E, CoQ10, and glutathione from their oxidized forms.
Diabetic neuropathy relief
Strongest clinical evidence: 600 mg/day ALA significantly reduces symptoms of peripheral diabetic neuropathy (pain, burning, numbness) in multiple RCTs, with therapeutic approval in Germany.
Insulin sensitivity
ALA activates GLUT4 glucose transporter translocation via PI3K and AMPK pathways, improving skeletal muscle glucose uptake. RCTs show reductions in fasting glucose and HOMA-IR.
Glutathione recycling
DHLA (reduced ALA) reduces oxidized glutathione (GSSG) back to active GSH, effectively amplifying the body's endogenous antioxidant capacity.
Mechanism of action
Mitochondrial cofactor activity
ALA is an essential cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — key enzyme complexes in the TCA cycle at the center of mitochondrial energy metabolism.
Nrf2 pathway activation
ALA activates the Nrf2-Keap1 pathway, inducing transcription of antioxidant response element (ARE) genes including glutathione peroxidase, superoxide dismutase, and heme oxygenase-1.
Metal chelation
ALA chelates redox-active metals (iron, copper, cadmium, mercury), preventing them from participating in Fenton reactions that generate hydroxyl radicals — particularly relevant in heavy metal toxicity.
Clinical trials
Multicenter, randomized, double-blind, placebo-controlled trial in 181 diabetic patients (Russia and Israel) with distal symmetric polyneuropathy. Once-daily oral ALA at 600 mg, 1,200 mg, 1,800 mg, or placebo for 5 weeks after 1-week placebo run-in. Primary outcome: change in Total Symptom Score (TSS). (Diabetes Care)
181 diabetic patients with distal symmetric polyneuropathy. 5-week intervention.
All ALA doses significantly improved TSS, NIS, and global assessment vs placebo. The 600 mg/day dose appeared optimal — providing therapeutic benefit with the best tolerability. Higher doses (1,200 and 1,800 mg) showed dose-dependent increases in nausea without proportional symptom improvement. Basis for therapeutic approval of ALA for diabetic neuropathy in Germany.
Randomized, controlled trial in 57 patients with type 2 diabetes randomized to ALA (300 mg/day) or placebo for 8 weeks. Outcomes: fasting blood glucose, 2-hour postprandial glucose, fasting insulin, insulin resistance (HOMA-IR), and glutathione peroxidase activity. (Saudi Medical Journal)
57 type 2 diabetes patients (14 men, 43 women, mean age 53). 8-week intervention.
ALA significantly reduced fasting blood glucose, postprandial glucose, fasting insulin, and HOMA-IR vs placebo. Glutathione peroxidase activity increased in the ALA group. No serious adverse events. Authors concluded ALA at 300 mg/day improves glycemic control and oxidative status in T2DM patients.
Multicenter, randomized, double-blind, placebo-controlled, 4-year trial in 460 diabetic patients with mild-to-moderate distal symmetric sensorimotor polyneuropathy. Oral ALA 600 mg/day vs placebo. Primary outcome: composite of Neuropathy Impairment Score-Lower Limb (NIS-LL) and 7 nerve conduction tests. (Diabetes Care)
460 diabetic patients with mild-moderate DSPN. 4-year intervention — longest ALA clinical trial.
Primary composite endpoint did not reach significance, but secondary endpoints (NIS-LL, neuropathic symptom scores) improved significantly with ALA. Importantly, ALA was safe and well-tolerated over 4 years. Authors concluded ALA improves sensory symptoms and signs of DSPN without increasing adverse events long-term.